MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Xilio Therapeutics, Inc. (XLO)

Xilio Therapeutics, Inc. (XLO)

|||

Balance Sheets Overview

Current Ratio
425.37%
Quick Ratio
425.37%
Cash Ratio
397.80%
Debt to Asset Ratio
53.15%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Less accumulated depreciation
    • Collaboration and license agreem...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Common stock warrant liabilities
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
136,040
150,333
137,531
103,764
License agreement receivable
-
-
-
17,500
Collaboration and license agreement receivable
6,000
0
5,000
-
Prepaid expenses and other current assets
3,428
3,874
2,496
2,825
Total current assets
145,468
154,207
145,027
124,089
Restricted cash
1,819
1,813
1,807
1,801
Property and equipment
12,768
12,777
12,645
12,139
Less accumulated depreciation
9,409
9,097
8,753
8,460
Property and equipment, net
3,359
3,680
3,892
3,679
Operating lease right-of-use asset
3,608
3,787
3,959
4,125
Total assets
154,254
163,487
154,685
133,694
Accounts payable
2,315
1,064
3,168
2,300
Accrued expenses
7,854
8,970
11,739
8,952
Deferred revenue, current portion
22,603
31,542
40,023
43,846
Operating lease liability, current portion
1,426
1,384
1,343
1,303
Total current liabilities
34,198
42,960
56,273
56,401
Deferred revenue, net of current portion
12,715
16,468
20,635
25,498
Operating lease liability, net of current portion
4,877
5,254
5,611
5,960
Common stock warrant liabilities
30,200
26,260
29,560
53,930
Liabilities to issue common stock
-
-
7,333
-
Total liabilities
81,990
90,942
119,412
141,789
Common stock, 0.0001 par value 600,000,000 shares authorized 6,580,149 shares issued and outstanding at june 30, 2026 4,530,641 shares issued and outstanding at december 31, 2025
1
1
-
5
Additional paid-in capital
506,954
500,862
454,062
421,049
Accumulated deficit
-434,691
-428,318
-418,789
-429,149
Total stockholders' equity
72,264
72,545
35,273
-8,095
Total liabilities and stockholders' equity
154,254
163,487
154,685
133,694
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$136,040K (11.92%↑ Y/Y)Collaboration and licenseagreement receivable$6,000K Prepaid expenses andother current assets$3,428K (58.34%↑ Y/Y)Property and equipment$12,768K (5.18%↑ Y/Y)Total current assets$145,468K (17.58%↑ Y/Y)Operating leaseright-of-use asset$3,608K (-15.80%↓ Y/Y)Property and equipment,net$3,359K (-16.40%↓ Y/Y)Restricted cash$1,819K (1.39%↑ Y/Y)Less accumulateddepreciation$9,409K (15.86%↑ Y/Y)Total assets$154,254K (15.28%↑ Y/Y)Total liabilities andstockholders' equity$154,254K (15.28%↑ Y/Y)Total liabilities$81,990K (-35.31%↓ Y/Y)Total stockholders'equity$72,264K (922.27%↑ Y/Y)Accumulated deficit-$434,691K (-5.29%↓ Y/Y)Total currentliabilities$34,198K (-35.79%↓ Y/Y)Common stock warrantliabilities$30,200K (-21.66%↓ Y/Y)Deferred revenue, net ofcurrent portion$12,715K (-55.59%↓ Y/Y)Operating leaseliability, net of current...$4,877K (-22.61%↓ Y/Y)Additional paid-in capital$506,954K (20.72%↑ Y/Y)Common stock, 0.0001par value...$1K (-80.00%↓ Y/Y)Deferred revenue,current portion$22,603K (-46.54%↓ Y/Y)Accrued expenses$7,854K (39.73%↑ Y/Y)Accounts payable$2,315K (-43.50%↓ Y/Y)Operating leaseliability, current portion$1,426K (12.82%↑ Y/Y)